Literature DB >> 31132431

FOXK transcription factors: Regulation and critical role in cancer.

Ying Liu1, Wei Ding2, Hu Ge3, Murugavel Ponnusamy1, Qiong Wang4, Xiaodan Hao1, Wei Wu1, Yuan Zhang1, Wanpeng Yu1, Xiang Ao5, Jianxun Wang6.   

Abstract

Growing evidence suggests that alterations of gene expression including expression and activities of transcription factors are closely associated with carcinogenesis. Forkhead Box Class K (FOXK) proteins, FOXK1 and FOXK2, are a family of evolutionarily conserved transcriptional factors, which have recently been recognized as key transcriptional regulators involved in many types of cancer. Members of the FOXK family mediate a wide spectrum of biological processes, including cell proliferation, differentiation, apoptosis, autophagy, cell cycle progression, DNA damage and tumorigenesis. Therefore, the deregulation of FOXKs can affect the cell fate and they promote tumorigenesis as well as cancer progression. The mechanisms of FOXKs regulation including post-translational modifications (PTMs), microRNAs (miRNAs) and protein-protein interactions are well demonstrated. However, the detailed mechanisms of FOXKs activation and deregulation in cancer progression are still inconclusive. In this review, we summarize the regulatory mechanisms of FOXKs expression and activity, and their role in the development and progression of cancer. We have discussed whether FOXKs act as tumor suppressors/oncoproteins in tumor cells and their therapeutic applications in malignant diseases are also discussed. This review may assist in designing experimental studies involving FOXKs and it would strength the therapeutic potential of FOXKs as targets for cancers.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; FOXK1; FOXK2; Therapeutic target; ncRNAs

Mesh:

Substances:

Year:  2019        PMID: 31132431     DOI: 10.1016/j.canlet.2019.05.030

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

Review 2.  Underlying mechanisms of epithelial splicing regulatory proteins in cancer progression.

Authors:  Ying Liu; Yiwen Li; Chengcheng Du; Shouxiang Kuang; Xuehao Zhou; Jinyu Zhang; Xiang Ao
Journal:  J Mol Med (Berl)       Date:  2022-09-27       Impact factor: 5.606

Review 3.  The FOXO family of transcription factors: key molecular players in gastric cancer.

Authors:  Ying Liu; Xiang Ao; Yi Jia; Xiaoge Li; Yu Wang; Jianxun Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-10       Impact factor: 5.606

Review 4.  Targets and regulation of microRNA-652-3p in homoeostasis and disease.

Authors:  Maxwell T Stevens; Bernadette M Saunders
Journal:  J Mol Med (Berl)       Date:  2021-03-12       Impact factor: 4.599

5.  Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.

Authors:  Shaoquan Zheng; Lu Yang; Yutian Zou; Jie-Ying Liang; Peng Liu; Guanfeng Gao; Anli Yang; Hailin Tang; Xiaoming Xie
Journal:  J Hematol Oncol       Date:  2020-03-05       Impact factor: 17.388

6.  PR-DUB maintains the expression of critical genes through FOXK1/2- and ASXL1/2/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination.

Authors:  Petros Kolovos; Koutarou Nishimura; Aditya Sankar; Simone Sidoli; Paul A Cloos; Kristian Helin; Jesper Christensen
Journal:  Genome Res       Date:  2020-08-03       Impact factor: 9.043

7.  Transcription factor forkhead box K1 regulates miR-32 expression and enhances cell proliferation in colorectal cancer.

Authors:  Weiyun Wu; Yongze Chen; Shicai Ye; Hui Yang; Jianyun Yang; Juanhua Quan
Journal:  Oncol Lett       Date:  2021-03-22       Impact factor: 2.967

8.  TIMELESS inhibits breast cancer cell invasion and metastasis by down-regulating the expression of MMP9.

Authors:  Bowen Li; Liying Mu; Yanan Li; Kangkai Xia; Yuxi Yang; Sattout Aman; Bashir Ahmad; Shujing Li; Huijian Wu
Journal:  Cancer Cell Int       Date:  2021-01-11       Impact factor: 5.722

Review 9.  Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer.

Authors:  Ying Liu; Xiang Ao; Guoqiang Ji; Yuan Zhang; Wanpeng Yu; Jianxun Wang
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

Review 10.  Targeting phosphatidylserine for Cancer therapy: prospects and challenges.

Authors:  Wenguang Chang; Hongge Fa; Dandan Xiao; Jianxun Wang
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.